Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€3.16

€3.16

-0.630%
-0.02
-0.630%
€11.05
 
25.04.24 / Stuttgart Stock Exchange WKN: A2N6SG / Symbol: STRO / Name: Sutro Biopharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Sutro Biopharma Inc Stock

Sutro Biopharma Inc shows a slight decrease today, losing -€0.020 (-0.630%) compared to yesterday.
Sutro Biopharma Inc is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
Based on the current price of 3.16 € the target price of 11 € shows a potential of 248.1% for Sutro Biopharma Inc which would more than double the current price.

Pros and Cons of Sutro Biopharma Inc in the next few years

Pros
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sutro Biopharma Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sutro Biopharma Inc -0.630% -9.143% 3.247% -23.188% -18.041% -81.183% -
Ardelyx Inc. 3.600% -2.578% -17.883% 40.048% 2.007% -13.927% -
Salarius Pharmaceuticals Inc. 1.400% -2.727% -46.500% -69.209% -22.883% -98.244% -99.994%
Brainstorm Cell -5.760% 3.754% -21.032% -81.975% 114.440% -80.717% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-11

Minimalistisch betrachtet scheint Sutro Biopharma, Inc., ein Unternehmen aus dem Bereich Biotechnologie und medizinische Forschung, das unter dem US-Symbol STRO geführt wird, einige bemerkenswerte finanzielle Eigenschaften zu besitzen. Mit einigen Schattierungen von roten Flaggen gibt es auch blinkende grüne Lichter, die einen zweiten Blick auf das Unternehmen rechtfertigen. Jetzt gilt es, die Vor- und Nachteile des Finanzprofils dieses Unternehmens abzuwägen.

Zunächst einmal brilliert das Unternehmen mit einem robusten Nettoumlaufvermögen von 202 Millionen Dollar im Jahr 2022 im Vergleich zu 176,7 Millionen und 348,5 Millionen Dollar in den Jahren 2021 bzw. 2020. Dieses starke Nettoumlaufvermögen unterstreicht die finanzielle Gesundheit des Unternehmens und seine Fähigkeit, kurzfristige Verbindlichkeiten zu bedienen.

Zudem verzeichnet das Unternehmen eine stetige Zunahme seines Anlagevermögens, das von etwa 15,9 Millionen im Jahr 2020 auf 65,4 Millionen im Jahr 2022 gestiegen ist. Es unterstreicht die Präsenz des Unternehmens in langfristige Investitionen, was ein positives Zeichen ist.

Comments

Prediction Buy
Perf. (%) -26.78%
Target price 7.385
Change
Ends at 03.04.25

Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -26.78%
Target price 10.159
Change
Ends at 03.04.25

Sutro Biopharma, Inc. (NASDAQ: STRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock, down previously from $12.00.
Ratings data for STRO provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -26.78%
Target price 9.249
Change
Ends at 03.04.25

Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Show more